Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging

Ohtsuka, Chigumi; Sasaki, Makoto; Konno, Kanako; Koide, Masafumi; Kato, Kuniki; Takahashi, Jun; Takahashi, Satoshi; Kudo, Kohsuke; Yamashita, Fumio; Terayama, Yasuo

doi:10.1016/j.neulet.2013.02.012

Cited by 154 publications

(161 citation statements)

References 21 publications

Supporting

Mentioning

127

Contrasting

Order By: Relevance

“…Sasaki and colleagues reported that both LC and SN can be imaged by using a T 1 -weighted turbo spin echo (TSE) sequence [8]. Other groups have also successfully applied similar spin echo techniques to study the LC and/ or SN [4,5,[9][10][11][12]. The size of the LC (a rod-shaped structure approximately 2-mm wide and 15-mm long) [13,14] dictates the need for an acquisition with high spatial resolution.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach

Chen

Huddleston

Langley

et al. 2014

Magnetic Resonance Imaging

125

167

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach

Chen

Huddleston

Langley

et al. 2014

Magnetic Resonance Imaging

125

167

View full text Add to dashboard Cite

“…High-field magnetic resonance imaging (MRI), such as 3 T, is very sensitive to tissue T1 relaxation and are able to depict tissue containing neuromelanin in (SNc) or (LC) [5]. There are many previous reports which showed the signal decrease in Parkinson’s disease using neuromelanin MRI [4], [6]–[10], but there are only two reports using this technique for schizophrenia [11], [12].…”

Section: Introductionmentioning

confidence: 99%

Neuromelanin Magnetic Resonance Imaging Reveals Increased Dopaminergic Neuron Activity in the Substantia Nigra of Patients with Schizophrenia

et al. 2014

View full text Add to dashboard Cite

PurposeThe dopamine hypothesis suggests that excessive dopamine release results in the symptoms of schizophrenia. The purpose of this study was to elucidate the dopaminergic and noradrenergic neurons using 3-T neuromelanin magnetic resonance imaging (MRI) in patients with schizophrenia and healthy control subjects.MethodsWe prospectively examined 52 patients with schizophrenia (M: F = 27∶25, mean age, 35 years) and age- and sex-matched healthy controls. Using a 3T MRI unit, we obtained oblique T1-weighted axial images perpendicular to the brainstem. We measured the signal intensity and area for the substantia nigra (SNc), midbrain tegmentum, locus ceruleus (LC), and pons. We then calculated the contrast ratios (CR) for the SNc (CRSN) and LC (CRLC), which were compared between patients and healthy controls using unpaired t-tests.ResultsThe SNc and LC were readily identified in both patients and healthy controls as areas with high signal intensities in the posterior part of the cerebral peduncle and in the upper pontine tegmentum. The CRSN values in patients were significantly higher than those in healthy controls (10.89±2.37 vs. 9.6±2.36, p<0.01). We observed no difference in the CRLC values between the patients and healthy controls (14.21±3.5 vs. 13.44±3.37, p = 0.25). Furthermore, there was no difference in area of the SNc and LC between schizophrenia patients and controls.ConclusionsNeuromelanin MRI might reveal increased signal intensity in the SNc of patients with schizophrenia. Our results indicate the presence of excessive dopamine products in the SNc of these patients.

show abstract

“…Neuromelanin, which can bind iron, is altered in PD and thereby may provide a potential diagnostic test [28,29,30,31,32,33,34,35,36,37,38,39,40]. …”

Section: Structural Imagingmentioning

confidence: 99%

Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson’s Disease (PD)

Tuite

2017

Brain Sciences

View full text Add to dashboard Cite

Magnetic resonance imaging (MRI) has the potential to serve as a biomarker for Parkinson’s disease (PD). However, the type or types of biomarker it could provide remain to be determined. At this time there is not sufficient sensitivity or specificity for MRI to serve as an early diagnostic biomarker, i.e., it is unproven in its ability to determine if a single individual is normal, has mild PD, or has some other forms of degenerative parkinsonism. However there is accumulating evidence that MRI may be useful in staging and monitoring disease progression (staging biomarker), and also possibly as a means to monitor pathophysiological aspects of disease and associated response to treatments, i.e., theranostic marker. As there are increasing numbers of manuscripts that are dedicated to diffusion- and neuromelanin-based imaging methods, this review will focus on these topics cursorily and will delve into pharmacodynamic imaging as a means to get at theranostic aspects of PD.

show abstract

Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging

Cited by 154 publications

References 21 publications

Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach

Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach

Neuromelanin Magnetic Resonance Imaging Reveals Increased Dopaminergic Neuron Activity in the Substantia Nigra of Patients with Schizophrenia

Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson’s Disease (PD)

Contact Info

Product

Resources

About